Onkologie. 2023:17(1):8-11 | DOI: 10.36290/xon.2023.003

Actual role of immunotherapy in a treatment of lung cancer

Monika Bratová
Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno

Immunotherapy plays an important role in management of lung cancer. Its incorporation in a treatment strategy helps to improve survival of patients with NSCLC and SCLC. Crucial principles of immunit control, check points and their inhibitors available in Czech Republic are discussed. Particular indications of immunotherapy for a diagnosis of lung cancer together with practical points and diagram of the first line treatment of NSCLC are presented.

Keywords: lung cancer, immunotherapy, NSCLC, SCLC.

Accepted: February 22, 2023; Published: March 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bratová M. Actual role of immunotherapy in a treatment of lung cancer. Onkologie. 2023;17(1):8-11. doi: 10.36290/xon.2023.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Novotvary 2018. Ústav zdravotnických informací a statistiky ČR; 2018: 149. Available from: https://www.uzis.cz/res/f/008352/novotvary2018.pdf.
    2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523-529. Go to original source... Go to PubMed...
    3. Bratova M, Karlinova B, Skrickova et al. Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry. In Vivo. 2020;34(1):369-379. Go to original source... Go to PubMed...
    4. Ramirez RA, Lu J, Thomas KEH. Quality of life for non-small cell lung cancer patients in the age of immunotherapy. Transl Lung Cancer Res. 2018;7(Suppl 2):S149-S152. Go to original source... Go to PubMed...
    5. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311. Go to original source... Go to PubMed...
    6. Metastatic NSCLC: ESMO Clinical Practice Guidelines for diagnosis, treatment and and folow-up; 2020. Available form: https://www.esmo.org/guidelines/guidelines-by-topic/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer [cited 28.12.2022].
    7. Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. Go to original source... Go to PubMed...
    8. Šťastný M, Říhová B. Únikové strategie nádorů pozornosti imunitního systému. Klin Onkol. 2015;28 Suppl 4:4S28-37. Go to original source... Go to PubMed...
    9. Ryška A. Mutace u nádorových onemocnění. In: Bauer J, Bajčiová V, Krajsová I. Imunologie a imunoterapie nádorů. Praha: Mladá fronta; 2018.
    10. Girard N, Bar J, Garrido P, Garassino MC, et al. Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. J Thorac Oncol. 2022 Oct 25:S1556-0864(22)01853-6.
    11. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. Go to original source... Go to PubMed...
    12. Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. Go to original source... Go to PubMed...
    13. Jassem J, de Marinis F, Giaccone G, et al. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. J Thorac Oncol. 2021;16(11):1872-1882. Go to original source... Go to PubMed...
    14. Awad MM, Gadgeel SM, Borghaei H, et al. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168. Go to original source... Go to PubMed...
    15. Paz-Ares L, Luft A, Vicente D, et al. KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051. Go to original source... Go to PubMed...
    16. Gettinger S, Horn L, Jackman D, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675-1684. Go to original source... Go to PubMed...
    17. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 Check Mate 227 Part 1 Trial. J Thorac Oncol. 2022;17(2):289-308. Go to original source... Go to PubMed...
    18. Gettinger S, Horn L, Jackman D, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675-1684. Go to original source... Go to PubMed...
    19. Mazieres J, Rittmeyer A, Gadgeel S, et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. J Thorac Oncol. 2021;16(1):140-150. Go to original source... Go to PubMed...
    20. Forde PM, Spicer J, Lu S, et al. CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. Go to original source... Go to PubMed...
    21. Chaft PA, Wistuba II, Kwiatkowski DJ, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155-2161. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.